Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma

Phei Er Saw1†, Xiaoding Xu1†, Bo Ram Kang3,4†, Jungsul Lee5, Yeo Song Lee3,4, Chungyeul Kim6, Hyungsin Kim7, Shin-Hyuk Kang7, Yoo Jin Na3,4, Hong Joo Moon4, Joo Han Kim4, Youn-Kwan Park4, Wonki Yoon4,8, Jong Hyun Kim4,8, Taek-Hyun Kwon4,8, Chulhee Choi5, Sangyong Jon2, Kyuha Chong3,4,8,9

1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, People’s Republic of China
2. Department of Biological Sciences, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea
3. Photo-Theranosis and Bioinformatics for Tumor Laboratory, Korea University Guro Hospital, Korea University Medicine, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul, 08308, Republic of Korea
4. Department of Neurosurgery, Korea University Guro Hospital, Korea University Medicine, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul, 08308, Republic of Korea
5. Department of Bio and Brain Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea
6. Department of Pathology, Korea University Guro Hospital, Korea University Medicine, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul, 08308, Republic of Korea
7. Department of Neurosurgery, Korea University Anam Hospital, Korea University Medicine, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea
8. Neurological Institute, Korea University Guro Hospital, Korea University Medicine, 148 Gurodong-ro, Guro-gu, Seoul, 08308, Republic of Korea
9. Graduate School of Medical Science and Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea

†These authors contributed equally to this work.

Corresponding author: Kyuha Chong. Email: kyuhaj@korea.ac.kr; Tel: +82-2-2626-1977; Fax: +82-2-2626-1976

Abstract

Extra-domain B of fibronectin (EDB-FN) is an alternatively spliced form of fibronectin with high expression in the extracellular matrix of neovascularized tissues and malignant cancer cells. In this study, we evaluated the practicality of using EDB-FN as a biomarker and therapeutic target for malignant gliomas (MGs), representative intractable diseases involving brain tumors.

Methods: The microarray- and sequence-based patient transcriptomic database ‘Oncopression’ and tissue microarray of MG patient tissue samples were analyzed. EDB-FN data were extracted and evaluated from 23,344 patient samples of 17 types of cancer to assess its effectiveness and selectivity as a molecular target. To strengthen the results of the patient data analysis, the utility of EDB-FN as a molecular marker and target for MG was verified using active EDB-FN–targeting ultrasmall lipidic micellar nanoparticles (~12 nm), which had a high drug-loading capacity and were efficiently internalized by MG cells in vitro and in vivo.

Results: Brain tumors had a 1.42-fold cancer-to-normal ratio (p < 0.0001), the second highest among 17 cancers after head and neck cancer. Patient tissue microarray analysis showed that the EDB-FN high-expression group had a 5.5-fold higher risk of progression than the EDB-FN low-expression group (p < 0.03). By labeling docetaxel-containing ultrasmall micelles with a bipodal aptide targeting EDB-FN (termed APTEDB-DSPE-DTX), we generated micelles that could specifically bind to MG cells, leading to superior antitumor efficacy of EDB-FN–targeting nanoparticles compared to nontargeting controls.

Conclusions: Taken together, these results show that EDB-FN can be an effective drug delivery target and biomarker for MG.

Key words: EDB-Fibronectin, Glioma, Big Data, Biomarkers, Micelles
Introduction

Malignant glioma (MG) is one of the most dreaded tumors, having no cure despite aggressive treatments. Glioblastoma multiforme (GBM), the most malignant and common type of glioma, has a median survival time of less than two years even with surgical and medical interventions [1, 2]. In addition to the highly proliferative and invasive features of MG, cellular heterogeneity along with the blood-brain barrier and blood-brain tumor barrier (BBTBR) hinder its treatment [3, 4]. To overcome these limitations, molecular and genetic studies and rearrangement of brain tumor classifications have become more crucial; the importance of these approaches has guided the incorporation of molecular biology into the pathological classification and revamping of diagnostic and therapeutic planning strategies.

Representative phenotypic-genotypic diagnostic markers that are currently implemented include O6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase promoter (MGMT) methylation, isocitrate dehydrogenase-1 (IDH-1) mutation, and chromosomal 1p/19q deletion, and the assessment of their status is profoundly affecting personalized treatment decisions and prognostic predictions [5, 6]. In addition, many other biomarkers, such as alpha-thalassemia/mental retardation syndrome X-linked and telomerase reverse transcriptase promoter mutations, are still undergoing validation, and their effectiveness is actively being verified [7]. However, most biomarkers evaluated and verified in MG to date have not yet been developed as therapeutic targets; only their usefulness for assessing drug acceptability or patient survival has been confirmed. Therefore, the discovery of biomarkers that can provide effective diagnostic and therapeutic import continues to be in demand.

Fibronectin is a glycoprotein found primarily in the extracellular matrix and plasma membrane. It regulates cell migration and adhesion while binding a variety of extracellular matrix proteins, such as integrin, collagen, and fibrin. Fibronectin monomers are classified into three types by their repeating units—type I, II, and III. Alternative splicing domains generated at three regions of the fibronectin gene generate several splicing patterns. The resulting isoforms are named according to the splice site location in the type III repeat unit: fibronectin with extra-domain A (EDA-FN), extra-domain B (EDB-FN), and the type III connecting segment (IIICS-FN) [8, 9]. EDB-FN is an oncofetal antigen. EDB-FN overexpression occurs in various human cancers, such as non-small cell lung carcinoma, Hodgkin lymphoma, and prostate cancer [10-12]. In addition, EDB-FN acts as an angiogenesis marker in head and neck cancer [13]. Regarding the role of fibronectins in the brain, EDB-FN is suggested for use as a tracing tool to diagnose primary GBM in patients [14] and as a novel target for GBM treatment, glioma radioimmunotherapy, in a rodent model [15, 16]. EDB-FN is considered a differentiated fibronectin isoform that can act as a cancer-specific marker and target [17, 18]. Although research on EDB-FN is actively being conducted, its roles are still being unveiled.

In this study, we investigated EDB-FN expression in MG and the relationship between EDB-FN and patient prognosis through patient sample-based big data analysis and tissue microarray. Moreover, to validate the proof-of-concept for the diagnostic and therapeutic utility of EDB-FN as a biomarker and a target in MG, in vitro and in vivo experiments were conducted following the development of an ultrasmall micellar lipidic nano-drug delivery system (DDS) specifically targeting EDB-FN.

Methods

Gene expression profiles and survival analysis

All gene expression profiles were downloaded from Oncopression [19], and data related to EDB-FN were collected by searching for fibronectin 1 (FN1, Entrez Gene ID: 2335), also known as FN or ED-B. Variants of the FN1 gene were investigated using ClinVar (https://www.ncbi.nlm.nih.gov/clinvar), and 126 variants were identified. Because the transcriptomic database analysis was aimed at screening expression levels in MG, analysis of the variants was not performed in this study. The transcriptomic expression levels of EDB-FN were normalized by Single Channel Array Normalization and Universal exPression Codes (SCAN.UPC) package of R [20] and presented as UPC values. More specifically, a single-sample normalization method [21] was used for Oncopression data and all samples were taken from the same Affymetrix Human Genome U133 Plus 2.0 (GPL570 or A-AFFY-44) platform. The expression values ranged from 0.0 to 1.0, where 1.0 indicates full transcriptional activation. The ‘cancer-to-normal’ ratio was calculated by dividing the cancer expression values by the mean normal expression values. For survival analysis, we collected brain tumor datasets containing expression profiles and patient prognostic information. After completing data collection, groups with fewer than 30 samples were excluded from the analysis. All gene expression values were quantile normalized by datasets. Z-values calculated from a log-rank test for each dataset were averaged by the Lipták method using the square root of the patient number of each dataset as the weight [22, 23].

http://www.thno.org
**Patient tissue microarray (TMA) sample preparation and interpretation**

Patient tissue samples donated and preserved in paraffin blocks after surgery and pathologic diagnosis were used from 21 adults aged 18 to 75 years who were diagnosed with GBM. TMA slides consisting of a total of 65 tissue samples from 3 to 4 different tumor sites per patient were prepared. Tissue cores 2 mm in diameter were carefully transferred to recipient paraffin blocks containing 45 holes per block. The filled recipient blocks were embedded in paraffin and 3 µm-thick sections were cut and mounted on slides. Tissue staining was followed by the method described below in the immunohistochemistry section. After immunostaining, we received readings from a pathologist on the level and presence of EDB-FN through a blind review. Staining intensity was scored from none or '1+' (very weak positive) to '4+' (very strong positive). Results of '1+' and '2+' were classified as low-expression group, and '3+' and '4+' were classified as high-expression group. The results of the EDB-FN expression level in TMA patient tissues were linked to each patient's clinical data in order to analyze the correlation between the expression and the patient’s prognosis. Patient prognosis was analyzed using overall survival and progression free survival (PFS) as variables.

**Materials**

Polyethylene glycol (2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (ammonium salt) (PEG2000-DSPE), DSPE-N-(lissamine rhodamine B sulfonyl) (ammonium salt) (Rh-DSPE), and N-maleimide-PEG2000-DSPE (ammonium salt) (Mal-PEG2000-DSPE) were purchased from Avanti Polar Lipids (CA, USA). The EDB-FN–specific peptide N’-CSSPIQGWSWTENGK(C)WTWGIIRLEQ-C’ was a custom-synthesized peptide ordered from Anygen Corp. (Gwangju, Republic of Korea). The mouse anti-EDB-FN antibody and anti-mouse fluorescein isothiocyanate (FITC)-conjugated secondary antibody were purchased from Abcam (Cambridge, UK). Docetaxel (DTX) and Sepharose CL-4B columns were purchased from Sigma-Aldrich (MO, USA), mounting solution was purchased from Dako Diagnostics (Glostrup, Denmark), and an Alamar Blue assay kit was purchased from Thermo Fisher Scientific (MA, USA). All reagents were laboratory grade and were used as received.

**Cell culture**

U87MG, U251MG, and U373MG cells were maintained at 37 °C in a humidified 5% CO2 environment. Cells were cultured in minimal essential medium (MCF7), RPMI (PC3, B16F10, B16F1) or Dulbecco’s modified Eagle’s medium (U87MG, U251MG, U373MG) supplemented with 10% fetal bovine serum (FBS; Gibco, IL, USA), 100 U/mL penicillin (Gibco), and 100 µg/mL streptomycin (Gibco). All cell culture media were purchased from Gibco.

**In vitro 3D spheroid culture**

For the 3D spheroid culture, all 3 MG cell lines (U87MG, U251MG, and U373MG) were seeded into a Nunclon Sphera Microplate 96-well round bottom plate (Thermo Fisher Scientific) at 1–5 × 10^5 cells per well. The plate was then centrifuged at 200 x g for 2 min before being placed in a 37 °C, 5% CO2 incubator. The cells were incubated for 6 days, and half of the medium was changed on the third day. For imaging, the formed spheroids were transferred to an 8-well chambered coverglass slide (Thermo Fisher Scientific), fixed with 4% (w/v) paraformaldehyde (Wako, VA, USA), and immunocytochemistry was performed as described in the staining section below.

**In vivo MG flank xenograft model for EDB-FN immunohistochemistry**

U87MG, U251MG, and U373MG cells were injected into the right flank of BALB/c nude mice at 5 × 10^6 cells per mouse to create flank subcutaneous xenograft mouse models (n = 1 mouse per group). Once the tumors reached a volume of 80–120 mm^3, mice were sacrificed and immunohistochemistry of the excised tumors was performed as described in the staining section below.

**Real-time quantitative reverse transcription-polymerase chain reaction**

Cells were collected, and ribonucleic acid (RNA) was extracted with RiboEx using an RNA isolation kit (GeneAll, Seoul, Republic of Korea). Complementary DNA (cDNA) was synthesized by reverse transcription using 1 µg of total RNA from each sample. The following genes were evaluated: the EDB-FN gene (forward primer: 5’-AATCCCATCACCATCTTCCA-3’; reverse primer: 5’-CGTTTGTTGTGTCAGTGTAG-3’); and the glyceraldehyde 3-phosphate dehydrogenase gene (forward primer: 5’-AATCCCATCACCATCTTCCA-3’; reverse primer: 5’-TGGACTCCACGACGTACTCA-3’). The polymerase chain reaction protocol consisted of an initial denaturation step at 94 °C for 5 min; 30 cycles at 94 °C for 1 min (denaturation), 55 °C for 1 min (annealing), and 72 °C for 2 min (extension); and a final extension step at 72 °C for 7 min [24]. One microgram of cDNA was added to 4 µL of ultrapure water, and 5 µL of SYBR Green real-time mixture (Takara, Tokyo, Japan)
was added prior to running the real-time polymerase chain reaction (Qiagen, Tokyo, Japan). The messenger RNA (mRNA) level of each gene was quantified using the ΔΔCt method and normalized to that of glyceraldehyde 3-phosphate dehydrogenase.

**Cell and Tissue Staining**

**Immunocytochemistry**

For 2D staining of 7 different cell lines, 10,000 cells were seeded on an 8-chambered cover glass slide 24 h before staining. For 3D staining, spheroids were moved from the cultured dish to the 8-well chambered coverglass slide. Incubated cells were rinsed three times with cold phosphate buffered saline (PBS; Welgene, Gyeongsan, Republic of Korea), fixed with 4% (w/v) paraformaldehyde for 15 min at room temperature, washed with PBS, permeabilized with 0.1% (v/v) Triton X-100 (Amresco, PA, USA)/PBS for 10 min, and incubated with primary antibody against EDB-FN (ab154210, 1:500 for 2D, 1:100 for 3D; Abcam) in 1% (w/v) bovine serum albumin (BSA; Millipore, MA, USA)/0.1% (v/v) Triton X-100/PBS at 4 °C overnight. After washing with PBS, immuno-labeled proteins were visualized by treatment with fluorescence-conjugated secondary antibodies for 60 min at room temperature. Cells were washed with PBS, mounted with 4',6-diamidino-2-phenylindole (DAPI) mounting medium (Vector laboratories, CA, USA), sealed with cover slips, and examined using a confocal laser scanning microscope (LSM 700; Carl Zeiss, NY, USA).

**Immunohistochemistry of paraffin-embedded TMA and animal samples**

The staining status of EDB-FN was analyzed by applying tissue microarray to patient tissue samples and immunohistochemistry to subcutaneous xenograft animal tissue samples. The TMA slides were dewaxed by heating at 55 °C for 30 min followed by three 5 min-washes with xylene and rehydration by 5 min-washes with 100, 95, and 80% (v/v) ethanol serially up to pure distilled water. Antigen retrieval was obtained by heating the sections at 95 °C for 30 min in 10 mM sodium citrate (pH 6.0). Endogenous peroxidase activity was blocked by incubation in 3% (w/v) hydrogen peroxide for 30 min. The background reactivity was removed using a universal blocking serum (Dako Diagnostics) for 30 min at room temperature. The slides were incubated for 1 h with antibodies specific to EDB-FN (orb227981, 1:50; Biorbyt, Cambridge, UK), and then for 30 min with a biotin-labeled secondary antibody. Streptavidin-peroxidase (Dako Diagnostics) was applied and developed. After slight counterstaining with hematoxylin, the slides were dehydrated and mounted under coverslips for microscopy.

**Synthesis of the active EDB-FN-targeting micellar nano-DDS**

**Synthesis of APTEDB-conjugated PEG2000-DSPE**

EDB-FN-specific aptamer-like peptide (APT<sub>EDB</sub>; Anygen) containing an additional cysteine residue was dissolved in dimethyl sulfoxide (Sigma-Aldrich), and Mal-PEG<sub>2000</sub>-DSPE was dissolved in chloroform (Sigma-Aldrich). The conjugation reaction was carried out at an APT<sub>EDB</sub>:Mal-PEG<sub>2000</sub>-DSPE molar ratio of 1:2 under inert conditions for 12 h at ambient temperature [16]. APT<sub>EDB</sub>-conjugated PEG<sub>2000</sub>-DSPE (APT<sub>EDB</sub>-DSPE) was purified by reversed-phase high-performance liquid chromatography, and the conjugation efficiency was determined using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. To remove unconjugated peptides, dialysis was carried out using a dialysis membrane (Spectrum Chemical, NJ, USA) with a molecular weight cutoff of 3.5 kDa. After 48 h, the conjugate was lyophilized.

**Preparation of micellar nano-DDSs with various weight percentages of APTEDB-DSPE**

An anionic lipid film of 2 mg/mL PEG<sub>2000</sub>-DSPE was prepared from the stock solution. To prepare fluorescently labeled micellar nano-DDSs, Rh-DSPE labeled with 0.5 wt% rhodamine B fluorophore was added to the PEG<sub>2000</sub>-DSPE solution, and APTEDB-DSPE was added to the formulation at a concentration of 1.0, 2.5, or 5.0 wt%. For example, to formulate the active targeting APTEDB-DSPE micellar nano-DDS (APT<sub>EDB</sub>-conjugated) with 1.0 wt% APTEDB-DSPE, 20 µg of the APTEDB-DSPE conjugate was added to 2 mg/mL of the PEG<sub>2000</sub>-DSPE solution containing 0.5 wt% Rh-DSPE. As a negative control, a passive/nontargeting PEG<sub>2000</sub>-DSPE micellar nano-DDS (APT<sub>EDB</sub>-unconjugated) was also synthesized. All components were added to a glass vial, dried under a vacuum, and further lyophilized overnight to remove any remaining chloroform. During rehydration, 1 mL of ultrapure water (Welgene) was added to the lipid film to yield a micellar solution with a final concentration of 2 mg/mL. Rehydration was performed under constant stirring at 1,000 revolutions per min to ensure the formation of uniform-sized micelles. Using Amicon® Ultra-15 centrifugal filter 3 kDa Units (Merck, Darmstadt, Germany), the solution in which micelles were dissolved was changed to PBS buffer. To remove oversized nanoparticles or aggregates, the solution was filtered through a 0.1-µm membrane (Millipore) and purified by size exclusion chromatography (CL-4B column; Merck). After preparation, the size

http://www.thno.org
and zeta potential of all micelle formulations in PBS were analyzed by dynamic light scattering (DLS) and zeta potential analysis. One milliliter of 2 mg/mL micelles was transferred into a transparent cuvette, and the hydrodynamic diameter and zeta potential of each micelle were measured using a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK).

**Synthesis and development of DSPE-DTX and APTEDB-DSPE-PTX**

Passive/nontargeting DSPE-PTX (APTEDB-unconjugated) and active targeting APTEDB-DSPE-PTX (APTEDB-conjugated) were developed by applying the method described above and a previously developed methodology [25]. First, cysteinylated APTEDB was conjugated to the maleimide group on the PEG2000-DSPE lipid to yield the APTEDB-DSPE lipid. For DTX loading, DTX was dissolved in chloroform and added to the micellar lipid film at a final concentration of 50 μg/mL during rehydration. The DTX-loaded PEG2000-DSPE micellar nano-DDS and APTEDB-DSPE micellar nano-DDS, termed ‘DSPE-PTX’ and ‘APTEDB-DSPE-PTX’, respectively, were then filtered through a 0.1-μm membrane and purified by size exclusion chromatography.

**Validation of EDB-FN as a therapeutic target for MG using APTEDB-conjugated micellar nanoparticles**

**In vitro cellular uptake of the APTEDB-DSPE micellar nano-DDS**

The cellular uptake efficiency of the APTEDB-DSPE micellar nano-DDS was determined by treating EDB-FN-positive U87MG and U251MG cells with each micelle formulation. U87MG and U251MG cells were seeded into a 96-well plate at 5,000 cells/well. After cells had grown to confluence on a sterilized coverslip, they were incubated for 1 h at 37 °C with 100 μg/mL PEG2000-DSPE micellar nano-DDSs or APTEDB-DSPE micellar nano-DDSs with an APTEDB-DSPE concentration of 1.0, 2.5, or 5.0 wt%. Cells were then washed with PBS, fixed with 4% (w/v) paraformaldehyde, counterstained with the nuclear dye DAPI (Invitrogen, CA, USA), mounted on glass slides, and examined to confirm the uptake rate of rhodamine B-labeled micelles by confocal laser scanning microscopy.

**In vitro cytotoxicity of APTEDB-DSPE-PTX to U87MG and U251MG cells**

To determine the value and usefulness of EDB-FN as a molecular target for MG, we encapsulated DTX into the core of PEG2000-DSPE and APTEDB-DSPE micellar nano-DDSs by the method described above. Cells were treated by coincubation with serial dilutions of each nano-DDS formulation for 24 h. After discarding the formulation, cells were further incubated for 24 h prior to the Alamar Blue assay (Bio-Rad, CA, USA). The IC₅₀ value for each formulation was determined by ProBit analysis.

**In vivo uptake of the APTEDB-DSPE micellar nano-DDS in the subcutaneous xenograft model**

To evaluate the uptake of the APTEDB-DSPE micellar nano-DDS in an *in vivo* xenograft model, U87MG cells were injected into the right flank of BALB/c nude mice (n = 3 mice per group) at 5 × 10⁶ cells/mouse. After 3 weeks, tumor growth was measured, and the tumor volumes were determined to be 80–120 mm³. Then, 200 μg of the PEG2000-DSPE micellar nano-DDS in PBS or APTEDB-DSPE micellar nano-DDS in PBS was injected into each mouse, and at predetermined time points (15, 30, 60, and 120 min), the tumor uptake of rhodamine B-labeled micelles was compared using an IVIS *in vivo* imaging system (PerkinElmer, MA, USA).

**In vivo antitumor efficacy of APTEDB-DSPE-PTX**

U87MG cells were injected into the right flank of BALB/c nude mice at 5 × 10⁶ cells per mouse to create flank subcutaneous xenograft mouse models. Once the tumors reached a volume of 80–120 mm³, mice were treated intravenously with saline, DSPE-PTX in PBS, or APTEDB-DSPE-PTX in PBS at a DTX concentration of 5 mg/kg (n = 5 mice per group, including n = 1 mouse per group for representative tumor tissue excision). Based on previous research protocols [26], each formulation was administered intravenously three times every other day for treatment. The tumor size was measured every three other days until excision. The tumor volume was calculated by the following formula: (length x width x height) x 0.5. The percentage of tumor inhibition was calculated by the following formula: \[ \left[ 1 - \frac{1}{(T\text{Day}_\text{E} - T\text{Day}_1) / (T\text{Day}_1 \times C\text{Day}_1) / (C\text{Day}_\text{E} - C\text{Day}_1)} \right] \times 100 \] (T\text{Day}_\text{E} = tumor volume of treatment group at the end of the experiment; T\text{Day}_1 = tumor volume of treatment group at Day 1; C\text{Day}_\text{E} = tumor volume of control group at the end of the experiment; C\text{Day}_1 = tumor volume of control group at Day 1).

To create orthotopic xenograft mouse models, the heads of BALB/c nude mice were fixed using a stereotactic device, and a small burr hole was made with a high-speed drill at 2 mm lateral to the bregma and 1 mm anterior to the coronal suture according to the method used by Ozawa and James [27]. U87MG cells were injected at a depth of 3 mm from the inner cortical bone of the skull using a 22-gauge needle (Hamilton Company, NV, USA) at 3 × 10⁵ cells per mouse. After 7 days, the mice were treated with...
saline, DSPE-DTX, or APT_{EDB}-DSPE-DTX at a concentration of 10 mg/kg DTX once intravenously (n = 4 mice per group). On the 21st day after transplantation, mice were sacrificed for tumor size analysis. After perfusion with 10% (v/v) formalin (Sigma-Aldrich), each brain was removed and embedded in an optimal cutting temperature compound (Sakura Finetek, Tokyo, Japan). The embedded brain samples were frozen and sliced into 20 μm by cryostat sectioning. The brain slices were stained using a hematoxylin and eosin (H&E) staining kit (ScyTek, UT, USA), and tumor volume was calculated by the following formula: (length x width x thickness) x 0.5. The longest dimension was set as the length, and the longest perpendicular diameter in the same plane was set as the width.

Imaging and statistical analysis

Image processing and data analysis were conducted using ImageJ software (http://rsb.info.nih.gov/ij/). All data were analyzed using GraphPad Prism 7 software (GraphPad, CA, USA) and are presented as the means ± standard deviations (std. devs.), except IC_{50} values, which are presented as the means ± standard errors (std. errors). Comparisons between groups were conducted primarily with an unpaired two-tailed t test with Welch’s correction (Welch’s t test) for normally distributed data and with the Mann-Whitney test for non-normally distributed data. P values of < 0.05 were considered statistically significant and are shown as p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) , and p < 0.0001 (****).

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the KAIST Institutional Animal Care and Use Committee and of the Korea University College of Medicine (IACUC No. KA2013-13 and KOREA-2019-0123). The patient sample study adhered to the guidelines and protocols approved by the Korea University Guro Hospital Institutional Review Board (IRB No. 2017GR0330).

Results

We analyzed normalized big data and patient tissue samples of EDB-FN expression levels to evaluate the feasibility of using EDB-FN as a marker and target among various cancers. In addition, we examined the usefulness of EDB-FN as a prognostic marker and as a drug delivery target in MG, one of the cancers with the highest cancer-to-normal EDB-FN expression ratio.

EDB-FN expression in human brain pathologies

EDB-FN expression in various organs and cancers

To verify the degree of EDB-FN expression in normal and cancer patient tissues, cancer-to-normal comparisons of EDB-FN in various organs and in brain tumors were performed using Oncopression. EDB-FN expression levels in 18,850 samples of a total of 17 cancers originating from various organs and 4,494 normal samples of each organ were compared and analyzed. Fifteen cancers showed a statistically significant difference in EDB-FN expression in cancer vs. normal tissues; however, no difference was found for adrenal and ureter cancers (Figure 1A, Table 1). Among the cancers, head and neck cancer and brain tumors exhibited the highest increase in the cancer-to-normal ratio of EDB-FN expression, approximately more than 1.42 (p < 0.001), which was high compared to that in other cancers.

Table 1. ‘Cancer-to-normal’ ratio of EDB-FN expression in carcinomas of various organs

| Organ    | Number of cancer samples | Number of normal samples | ‘Cancer-to-normal’ ratio (mean ± std. dev., A.U.) | Cancer vs normal p value |
|----------|--------------------------|--------------------------|--------------------------------------------------|--------------------------|
| Brain    | 2517                     | 723                      | 1.420 ± 0.229                                    | < 0.0001                 |
| Head and Neck | 360                     | 119                      | 1.561 ± 0.358                                    | < 0.0001                 |
| Oral     | 309                      | 167                      | 1.296 ± 0.323                                    | < 0.0001                 |
| Thyroid  | 338                      | 197                      | 1.374 ± 0.305                                    | < 0.0001                 |
| Lung     | 2502                     | 650                      | 1.195 ± 0.279                                    | < 0.0001                 |
| Breast   | 5516                     | 471                      | 1.284 ± 0.253                                    | < 0.0001                 |
| Gastric  | 934                      | 110                      | 1.168 ± 0.152                                    | < 0.0001                 |
| Liver    | 524                      | 322                      | 1.077 ± 0.206                                    | < 0.0001                 |
| Pancreatic | 240                     | 98                       | 1.325 ± 0.405                                    | < 0.0001                 |
| Colon    | 2449                     | 500                      | 1.109 ± 0.217                                    | < 0.0001                 |
| Adrenal  | 355                      | 50                       | 0.966 ± 0.171                                    | nonsignificant           |
| Renal    | 504                      | 195                      | 1.181 ± 0.196                                    | < 0.0001                 |
| Ureter   | 58                       | 45                       | 0.919 ± 1.058                                    | nonsignificant           |
| Ovarian  | 1146                     | 92                       | 1.265 ± 0.324                                    | < 0.0001                 |
| Uterine  | 387                      | 192                      | 1.103 ± 0.329                                    | < 0.05                   |
| Prostate | 257                      | 75                       | 1.419 ± 0.528                                    | < 0.0001                 |
| Skin     | 454                      | 488                      | 1.042 ± 0.173                                    | < 0.0001                 |

Statistical analysis: Mann-Whitney test. A.U.: arbitrary unit; std. dev: standard deviation.

EDB-FN expression in human brain pathologies and brain tumors

To specifically analyze EDB-FN expression in the brain, we analyzed a total of 3,687 samples of various brain pathologies, including brain tumors, according to the grade and molecular biological status (Figure 1B, Table 2). Analysis of nontumor brain pathologies indicated no significant difference in EDB-FN expression between tissues of Parkinson’s disease patients compared to normal brain tissues. However, a significant decrease in EDB-FN expression was observed in tissues of patients with Alzheimer’s dementia (p < 0.0001), and an increase was observed...
in tissues of patients with major depressive disorder \( (p < 0.001) \) and epilepsy \( (p < 0.05) \).

In brain tumor tissues, EDB-FN expression was universally increased regardless of grade or molecular status compared to normal tissues, with a \( p \) value of \( < 0.0001 \). Grade IV brain tumors showed the highest EDB-FN expression levels (an increase of approximately 1.5-fold relative to normal tissues). EDB-FN expression levels increased as grades progressed from I to IV (grade I, 1.3-fold; grade II, 1.3-fold; grade III, 1.4-fold; grade IV, 1.5-fold). There was no significant difference in EDB-FN expression in grades I and II, but there was a significant difference between grades II and III \( (p < 0.0001) \), as well as between grades III and IV \( (p < 0.0001) \). In the analysis of MGMT and IDH-1, which are representative molecular biomarkers of brain tumors, EDB-FN expression between the MGMT methylated group and MGMT unmethylated group did not show any significant difference (both 1.5-fold). However, although the fold difference between the two groups was small, EDB-FN expression in the IDH-1 wild-type group, which is known to have a worse prognosis, was significantly higher than in the IDH-1 mutated group (IDH-1 mutated, 1.3-fold; IDH-1 wild-type, 1.4-fold, \( p < 0.0001 \)). These results suggest that EDB-FN can be a useful target for brain tumors, especially MG, regardless of the molecular status.

![Figure 1](http://www.thno.org)

**Figure 1.** Extra-domain B of fibronectin (EDB-FN) expression in human brain pathologies. Patient sample-based transcriptomic database ‘Oncopression’ analysis. (A) The ‘cancer-to-normal’ ratio of EDB-FN expression in the 17 major organs. Total of 18,850 cancer samples and 4,494 normal samples were analyzed. The Mann-Whitney test was used for statistical analysis. The data are presented as the means ± 95% confidence interval. (B) EDB-FN expression in various brain pathologies, including malignant glioma (MG). Total of 3,687 samples of brain pathologies were analyzed. Expression levels of the other brain pathologies and of the brain tumor grades were compared with the value of normal brain. The Mann-Whitney test was used for statistical analysis. The results are presented as Universal exPression Codes (UPC) value. (C) Relationship between EDB-FN expression and prognosis of GBM patients. Total of 1,615 samples from 21 glioblastoma multiforme datasets were analyzed. The negative Z-value indicates a worse prognosis. The integrated Z-value was obtained by using Lipták’s method. The black circles indicate the Z-value of each dataset, and a Kaplan-Meier survival curve was generated. (D) Correlation between EDB-FN expression and survival in GBM patients. Twenty-one patients with GBM were analyzed. Survival analysis was performed by integrating the patient’s clinical data and EDB-FN expression level. TMA scale bar = 2 mm. Kaplan-Meier survival curve was generated. * \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \), **** \( p < 0.0001 \), ns: not statistically significant. AD: Alzheimer’s dementia; EDB-FN: extra-domain B of fibronectin; GBM: glioblastoma multiforme; IDH-1: isocitrate dehydrogenase-1; MDD: major depressive disorder; MGMT: O6-methylguanine-deoxyribonucleic acid methyltransferase promoter; PD: Parkinson’s disease; UPC: Universal exPression Codes value.
Furthermore, the analysis of the expression of EDB-FN in brain tumors was analyzed in detail as a typical brain tumor type, astrocytoma. Except that the statistical difference between grade I astrocytoma and grade III astrocytoma was enhanced from \( p < 0.01 \) to \( p < 0.0001 \), EDB-FN expression in astrocytoma showed similar trends and differences with the results of analyzing EDB-FN expression by grade for all brain tumors. IDH-1 comparative analysis in astrocytoma was excluded because it did not meet the analysis conditions requiring there to be 30 or more samples in the group.

**EDB-FN as a prognostic biomarker for GBM**

As an additional assessment of clinical significance, the applicability of EDB-FN as a prognostic biomarker in brain tumors, especially in the GBM group with the highest EDB-FN expression levels (‘grade IV’), was analyzed using quantile normalization values from the datasets. For prognostic analysis, EDB-FN expression values in a total of 1,615 samples from 21 GBM datasets were classified into high- and low-expression groups based on the median expression values, and overall survival analysis was performed (Figure 1C, Table S1). The integrated Z-value of EDB-FN expression in GBM was \(-0.97\) (\( p < 0.33 \)), indicating that high EDB-FN expression in GBM patients may point to worse overall survival prognoses but have no statistically significant value (Figure 1C).

We performed TMA analysis using patient samples for in-depth and direct confirmation of *in silico* data. The expression of EDB-FN in GBM tissues and the overall survival and progression free survival of patients corresponding to each tissue were analyzed (Figure 1D). We used tissue samples from a total of 21 patients, 13 males and 8 females with a mean age of 51.0 years, who were diagnosed pathologically with GBM. Positive staining results in all 21 patients and 98.5% of samples from the patients (64 out of 65; negative staining, 1 sample, 1.5%; ‘1+’, 15 samples, 23.1%; ‘2+’, 17 samples, 26.2%, ‘3+’, 28 samples, 43.1%; ‘4+’, 4 samples, 6.2%) confirmed that EDB-FN may be useful as a cancer diagnostic biomarker in GBM. To summarize by reclassifying the EDB-FN low-expression group and high-expression group as the mean value of the staining results for each patient, the low-expression group was 71.4% (15 of 21 patients) and the high-expression group was 28.6% (6 of 21 patients). The difference between overall survival and progression free survival was analyzed between the two groups. The difference in overall survival between the EDB-FN low- and high-expression groups was not as statistically significant (\( p < 0.36 \); hazard ratio = 2.12; 95% confidence interval = 0.42-10.78) as *in silico* Oncopression analysis result. However, the median of progression free survival between the groups was significantly different (\( p < 0.03 \); low-expression, 105.0 days; high-expression, 111.4 days; high-expression, 105.0 days). The EDB-FN high-expression group had a more than 5.5-fold increased risk of progression compared to the low-expression group (hazard ratio = 5.53; 95% confidence interval = 1.22-25.05).

**EDB-FN expression in cancer cell lines**

We screened various human cancer cell lines to determine their EDB-FN expression levels. The breast cancer cell line MCF7, prostate cancer cell line PC3, melanoma cell lines B16F1 and B16F10, and MG cell lines U373MG, U87MG, and U251MG were used in experiments. The expression pattern of the EDB-FN protein was confirmed for qualitative analysis during the two-dimensional monolayer culture (Figure 2A). Weak EDB-FN expression was detected in the PC3 cell line and the U373MG cell line, but noticeable expression was observed in the U87MG cell line. In addition, qRT-PCR was performed by extracting mRNA for quantitative analysis of EDB-FN expression (Figure 2B). As a result (MCF7, 47.8 ± 7.9; PC3, 12.1 ± 2.1; B16F1, 0.6 ± 0.5; B16F10, 23.3 ± 1.4; U373MG, 2.6 ± 0.8; U251MG, 643.0 ± 31.0; U87MG, 1430.3 ± 61.4), statistically significant overexpression was observed in U251MG (\( p < 0.001 \), compared to all other cell lines).

---

**Table 2. EDB-FN expression in normal brain and various brain pathologies**

| Pathology | Number of samples | Mean expression | Standard deviation | Difference from normal (fold) | Difference from normal, \( p \) value |
|-----------|-------------------|----------------|-------------------|------------------------------|-----------------------------------|
| Normal    | 723               | 0.408 ± 0.132  | -                 | -                            | -                                 |
| AD        | 227               | 0.329 ± 0.171  | -                 | 0.808                         | < 0.0001                          |
| MDD       | 134               | 0.454 ± 0.048  | 1.114             | 0.05                          |                                    |
| Epilepsy  | 43                | 0.440 ± 0.120  | 1.079             | < 0.05                        |                                    |
| PD        | 51                | 0.429 ± 0.088  | 1.054             | non-significant               |                                    |
| Grade I   | 88                | 0.534 ± 0.124  | 1.311             | < 0.0001                      |                                    |
| Grade II  | 267               | 0.549 ± 0.076  | 1.347             | < 0.0001                      |                                    |
| Grade III | 310               | 0.573 ± 0.069  | 1.406             | < 0.0001                      |                                    |
| Grade IV  | 274               | 0.627 ± 0.099  | 1.539             | < 0.0001                      |                                    |
| MGMT methylated | 44 | 0.608 ± 0.038 | 1.492 | < 0.0001 |                                    |
| MGMT unmethylated | 34 | 0.610 ± 0.031 | 1.497 | < 0.0001 |                                    |
| IDH-1 mutated | 136 | 0.547 ± 0.060 | 1.341 | < 0.0001 |                                    |
| IDH-1 wild-type | 79 | 0.569 ± 0.052 | 1.397 | < 0.0001 |                                    |
| Astrocytoma, grade I | 74 | 0.535 ± 0.127 | 1.312 | < 0.0001 |                                    |
| Astrocytoma, grade II | 134 | 0.552 ± 0.083 | 1.355 | < 0.0001 |                                    |
| Astrocytoma, grade III | 132 | 0.586 ± 0.070 | 1.439 | < 0.0001 |                                    |
| GBM, grade IV | 865 | 0.625 ± 0.094 | 1.534 | < 0.0001 |                                    |
| GBM, MGMT methylated | 44 | 0.608 ± 0.038 | 1.492 | < 0.0001 |                                    |
| GBM, MGMT unmethylated | 34 | 0.610 ± 0.031 | 1.497 | < 0.0001 |                                    |

Statistical analysis: Mann-Whitney test, GBM: glioblastoma multiforme, MGMT: O6-methylguanine-deoxyribonucleic acid methyltransferase promoter, IDH-1: isocitrate dehydrogenase-1.

---

http://www.thno.org
other cell lines, Welch’s t test), and the highest expression was seen in U87MG cell line ($p < 0.001$, compared to all other cell lines, Welch’s t test). Through these results, it was confirmed that EDB-FN was more overexpressed in MG when compared with other cancers.

To realize the tumor microenvironment, MG cell lines were cultured in 3D, and an MG flank xenograft animal model was constructed. Qualitative analysis of EDB-FN expression using immunostaining revealed that EDB-FN was more overexpressed in U87MG cell lines than in U251MG and U373MG cell lines during 3D culturing (Figure 2C). In the xenograft mouse model, the U251MG and U87MG cell lines showed relatively higher expression patterns than those of the U373MG cell lines (Figure 2D). In the quantitative analysis through mRNA qRT-PCR (Figure 2E), EDB-FN was highly expressed in the 2D cultured U87MG cell line ($p < 0.01$, Welch’s t test) compared to the 2D cultured U373MG cell line. Compared to it, the U87MG cell line showed higher EDB-FN expression in 3D culture ($p < 0.001$, compared to 2D cultured U87MG, Welch’s t test), which mimics the tumor microenvironment, and the highest EDB-FN expression when xenografted into animals ($p < 0.0001$, compared to 3D cultured U87MG, Welch’s t test). These results imply a linear correlation between EDB-FN expression and tumor microenvironment similarity in MG, indicating the feasibility of using EDB-FN as a cancer biomarker for MG.

Collectively, it appears that EDB-FN is overexpressed in MG cells compared to other cancer cells. And among MG cell lines, relatively low expression of EDB-FN appears in U373MG cells that proliferate slowly [28]. U87MG, which exhibits features of aggressive proliferation, exhibited the highest EDB-FN expression level, followed by U251MG, which has GBM stem-like cell characteristics [29]. Based on these results, U87MG and U251MG cell lines were used in the subsequent study.

Figure 2. Overexpression of EDB-FN in MG cells. To verify the expression level of EDB-FN, (A) EDB-FN expression pattern in 2D cultures of various cancer cell lines (scale bar = 100 µm). Green represents EDB-FN; Blue represents 4’,6-diamidino-2-phenylindole (DAPI). (B) EDB-FN mRNA expression analysis using quantitative real-time PCR (qRT-PCR) after extracting total RNA from each 2D cultured cell line of various cancers. 2^{-\Delta\Delta C_T} was used and glyceraldehyde 3-phosphate dehydrogenase was set as the inner control. Confirmation of EDB-FN expression pattern through immunofluorescence staining in 3D culture (scale bar = 200 µm) (C) and subcutaneous transplanted cancer tissues (scale bar = 100 µm) (D) of MG cell lines. (E) qRT-PCR analysis using total RNA extracted from U373MG cells (2D monolayer culture) or U87MG cells (2D monolayer culture, 3D spheroid, and subcutaneous tumor tissue). Statistical analysis: Welch’s t test. *$p < 0.01$, **$p < 0.001$, ***$p < 0.0001$, ns: not statistically significant. The results are presented as the means ± standard deviations of quadruplet determinations. EDB-FN: extra-domain B of fibronectin; MG: malignant glioma.
Characteristic analysis of the synthesized APTEDB-DSPE micellar nano-DDS

DLS analysis of the micelles showed diameters of 11.5 ± 1.9 nm for the PEG2000-DSPE micellar nano-DDS and 8.2 ± 1.3 nm, 10.5 ± 1.9 nm, and 10.3 ± 1.3 nm for the APTEDB-DSPE micellar nano-DDS with APTEDB-DSPE concentrations of 1.0, 2.5, and 5.0 wt%, respectively (Figure 3A and B). The decrease in the DLS-measured size of the APTEDB-DSPE micellar nano-DDS compared to that of the PEG2000-DSPE micellar nano-DDS and the increase in the measured size of the APTEDB-DSPE micellar nano-DDS at APTEDB-DSPE concentrations of 2.5 and 5.0 wt% compared to that of the same DDS at 1.0 wt% indicate that the presence of APTEDB on the outer surface of the micelles may influence conformational changes in the micellar nano-DDSs. The zeta potential, from which the surface charge of the nanoparticles can be deduced, was measured for each nano-DDS; the zeta potentials were -9.3 ± 1.1 mV for the PEG2000-DSPE micellar nano-DDS and -9.5 ± 0.7 mV, -10.4 ± 1.3 mV, and -12.1 ± 0.7 mV for the APTEDB-DSPE micellar nano-DDS with APTEDB-DSPE concentrations of 1.0, 2.5, and 5.0 wt%, respectively (Figure 3C).

Cellular uptake depends on the APTEDB-DSPE density

To determine the optimal targeting ligand density, APTEDB-DSPE was added to a chloroform solution of Rh-DSPE mixed with PEG2000-DSPE at concentrations of 1.0, 2.5, and 5.0 wt% prior to formation of the lipid film. Under all conditions, the uptake efficacy of the active targeting APTEDB-DSPE micellar nano-DDS in cancer cells was higher than that of the passive/nontargeting PEG2000-DSPE micellar nano-DDS (Figure 4A). Interestingly, the APTEDB-DSPE micellar nano-DDS with an APTEDB-DSPE concentration of 2.5 wt% showed the highest cellular uptake in U251MG cells (PEG2000-DSPE, 44.5 ± 9.6; 1.0% APTEDB-DSPE, 76.4 ± 8.1; 2.5% APTEDB-DSPE, 128.8 ± 12.1; 5.0% APTEDB-DSPE, 53.4 ± 5.1), whereas the APTEDB-DSPE micellar nano-DDS with an APTEDB-DSPE concentration of 1.0 wt% showed the highest cellular uptake in U87MG cells (PEG2000-DSPE, 6.8 ± 5.1; 1.0%
**EDB-FN–targeting enhances cancer targeting and anticancer efficacy**

*In vitro* cytotoxicity of APTEDB-DSPE-DTX

To determine the value and usefulness of EDB-FN as a molecular target for MG, we encapsulated DTX into the core of PEG2000-DSPE and APTEDB-DSPE micellar nano-DDSs. The loading capacity of each micellar nano-DDS was calculated to be 10 wt%, with an encapsulation efficacy of ~95%. Cell viability was evaluated using DSPE-DTX and APTEDB-DSPE-DTX (Figure 4B). Although the DTX in both the DSPE-DTX and APTEDB-DSPE-DTX systems inhibited the viability of U251MG and U87MG cells, the degree of inhibition differed. The IC₅₀ values in U87MG cells were 87.38 ± 6.87 nM for DSPE-DTX and 23.15 ± 1.67 nM for APTEDB-DSPE-DTX, approximately 3.8-fold lower for APTEDB-DSPE-DTX than for DSPE-DTX (p < 0.0001, Welch’s t test). The IC₅₀ values in U251MG cells were 43.16 ± 7.05 nM for DSPE-DTX and 26.20 ± 1.53 nM for APTEDB-DSPE-DTX, approximately 1.6-fold lower for APTEDB-DSPE-DTX than for DSPE-DTX (p < 0.05, Welch’s t test) (Figure 4C). The *in vitro* cellular toxicity data in U87MG and U251MG cells implied that superior cancer targeting and increased drug uptake may be achieved with active targeting of EDB-FN compared to passive/nontargeting. Since a significant difference in the IC₅₀ values of DSPE-DTX and APTEDB-DSPE-DTX was observed in U87MG cells, U87MG cells were selected for *in vivo* modeling and evaluation of EDB-FN as a molecular target for MG.

*In vivo* uptake of the APTEDB-DSPE micellar nano-DDS

In the real-time IVIS imaging study in the U87MG flank xenograft mouse model, the APTEDB-DSPE micellar nano-DDS showed a significant increase in tumor localization compared to the passive/nontargeting PEG₂₀₀₀-DSPE micellar nano-DDS; this increase in tumor localization was observed consistently from 15 min to 120 min (Figure 5A). At 15 min, minimal nanoparticle accumulation could be seen. After 30 min, the APTEDB-DSPE micellar nano-DDS group started to show higher accumulation. After 60 min, the APTEDB-DSPE micellar nano-DDS group exhibited greater accumulation of the DDS at the tumor site than the PEG₂₀₀₀-DSPE micellar nano-DDS group. In addition, tissue uptake of the micellar nano-DDSs was observed for 48 h to determine if the DDSs affect organs other than tumors (Figure S3A). The passive/nontargeting PEG₂₀₀₀-DSPE micellar nano-DDS gradually spread throughout the body within 48 h. However, the APTEDB-DSPE micellar nano-DDS was found to remain stable, confined to the tumor site.
results indicate the stability and high MG-targeting ability of the APTEDB-DSPE micellar nano-DDS. The EDB-FN-targeting ability of APTEDB-DSPE may have significantly increased the retention time of the APTEDB-DSPE micellar nano-DDS in MG by binding to EDB-FN with high affinity, which in turn increased the bioavailability of the drug in the tumor.

**In vivo anticancer efficacy of APTEDB-DSPE-DTX**

The *in vivo* anticancer efficacy was examined in the U87MG subcutaneous xenograft animal model. The efficacy was evaluated by comparing the trend of tumor growth over time in the control, DSPE-DTX, and APTEDB-DSPE-DTX groups (Figure 5B). The tumor volume in the control group increased approximately 5.9-fold within 16 days relative to the volume on day 1 (Day 1: 91.5 ± 7.4 mm^3 vs. Day 17: 538.0 ± 115.9 mm^3; p < 0.01, Welch’s *t* test). Tumor growth was significantly inhibited by treatment with either DSPE-DTX or APTEDB-DSPE-DTX. By calculating the percentage of tumor inhibition as described in ‘Materials and Methods’, we found that DSPE-DTX inhibited tumor growth by approximately 54.8% (Day 1: 87.9 ± 12.6 mm^3 vs. Day 17: 281.7 ± 29.4 mm^3; p < 0.001, Welch’s *t* test), whereas APTEDB-DSPE-DTX significantly inhibited tumor growth by approximately 97.6% (Day 1: 87.5 ± 12.6 mm^3 vs. Day 17: 97.8 ± 2.6 mm^3; p < 0.20, Welch’s *t* test). At day 1, tumor volume did not differ significantly between groups. However, after three doses of nano-DDS injections on days 2, 4, and 6, the difference in tumor volume between groups became significant over time (Figure 5C and D). The APTEDB-DSPE-DTX group showed significant tumor inhibition beginning on day 7 compared to the control group (p < 0.001, Welch’s *t* test) and beginning on day 17 compared to the DSPE-DTX group (p < 0.01, Welch’s *t* test).

![Figure 4](image-url) *In vitro* cellular uptake and cytotoxicity of the APTcis-DSPE and APTcis-DSPE-DTX micellar nano-DDS. (A) Cell uptake of rhodamine B fluorochrome-labeled nano-DDSs according to the concentration of APTEDB-DSPE in MG (left). Red: nano-DDSs, Blue: DAPI, Scale bar = 100 µm. Quantification analysis of the APTEDB-DSPE micellar nano-DDS cellular uptake via ImageJ (right). Fluorescence intensity was normalized to the DAPI signal of each cell line (quadruplet determinations). (B) *In vitro* cytotoxicity of DSPE-DTX and APTEDB-DSPE-DTX to U251MG and U87MG cells. % cell viability on the Y-axis was calculated by dividing the O.D. value under nano-DDS treatment by the O.D. value under PBS treatment (7 replicates for DSPE-DTX and 6 replicates for APTEDB-DSPE-DTX). (C) The IC50 values in U87MG and U251MG cells were calculated according to the types of nanoparticles used for treatment (7 replicates for DSPE-DTX and 6 replicates for APTEDB-DSPE-DTX). Statistical analysis: Welch’s *t* test. *p* < 0.05, **p** < 0.01, ***p*** < 0.001, ****p*** < 0.0001, ns: not statistically significant. The results are presented as the means ± standard deviations. A.U: arbitrary unit. APTcis-DSPE: APTcis-conjugated PEG2000-DSPE; APTEDB-DSPE-DTX: DTX-loaded APTEDB-DSPE micellar nano-DDS; DSPE-DTX: DTX-loaded PEG2000-DSPE micellar nano-DDS; DTX: docetaxel; PEG2000-DSPE: polyethylene glycol (2000)-DSPE (ammonium salt).
Figure 5. In vivo uptake and anticancer efficacy of APTEDB-DSPE-DTX. In U87MG subcutaneous xenograft mouse model, (A) IVIS rhodamine B real-time imaging of PEG2000-DSPE micellar nano-DDS vs. APTEDB-DSPE micellar nano-DDS uptake in a U87MG xenograft tumor-bearing rodent model (n = 3 mice per group). Scale bar = 10 mm. (B) U87MG xenograft tumor growth curves according to drug treatment. The tumor size in mice was measured every 3 days (n = 4 mice per group). The red arrow indicates the drug IV infusion schedule. (C) Anticancer effect of micelle nano-DDSs. Changes in tumor size according to treatment with DSPE-DTX, APTEDB-DSPE-DTX, or saline as the negative control were compared (n = 4 mice per group). (D) Representative images of excised tumors from the xenograft model. Drug-treated mice were sacrificed on day 7, 10, 14, and 17 respectively (n = 1 mouse per group). Scale bar = 10 mm. In U87MG orthotopic xenograft mouse model, (E) Experimental schedule for orthotopic model. (F) Inhibitory effect of micelle nano-DDSs on malignant brain tumor (n = 4 per group). Brain slices with the largest tumor volume in all subjects were selected and analyzed. (G) Representative image for comparison of brain tumor size. The mouse brain was sectioned to a thickness of 20 μm, and brain tumors were identified by H&E staining. Scale bar = 1 mm. Statistical analysis: Welch’s t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns: not statistically significant. The results are presented as the means ± standard deviations. APTEDB-DSPE-DTX: docetaxel-loaded APTEDB-DSPE micellar nano-DDS; DDS: drug delivery system; DSPE-DTX: docetaxel-loaded PEG2000-DSPE micellar nano-DDS; DTX: docetaxel; nano DDS Tx: nano drug delivery system treatment.

As shown in Figure S3B, no adverse event was observed in major organs such as the heart, liver, spleen, lung, and kidney due to the treatment of micelle nano-DDSs in the body, and there was no significant change in mouse weight until the end of the experiment (Day 1, control = 20.4 ± 0.6 g, DSPE-DTX = 21.4 ± 0.2 g, APTEDB-DSPE-DTX = 18.9 ± 0.6 g; Day 17, control = 19.8 ± 1.6 g, DSPE-DTX = 20.7 ± 1.2 g, APTEDB-DSPE-DTX = 19.5 ± 0.9 g) (Figure S3C). This indicates that APTEDB-DSPE micelle nano-DDS is biocompatible in vivo due to its insignificant toxicity.

Anticancer efficacy of APTEDB-DSPE-DTX in orthotopic brain tumor mouse model

To evaluate its practicality as a target for the treatment of brain tumors, we constructed a U87MG orthotopic xenograft animal model. As shown in Figure 5E, saline as a control, DSPE-DTX and APTEDB-DSPE-DTX were injected via intravenous injection 7 days after cell transplantation (n = 4 mice per group). After 2 weeks, the brain was extracted and the tumor volume of each group was compared. Localization of the normal and tumor areas of sliced brain tissues was performed using H&E staining, and the volume of tumor was measured based on the slice in which the tumor was the largest in each individual (Figure 5F and G). As a result, we found that tumor growth was significantly inhibited by EDB-FN-targeting micelle nano-DDS treatment. Compared to the control group (116.9 ± 21.0 mm³), DSPE-DTX (86.7 ± 28.7 mm³) and APTEDB-DSPE-DTX (46.5 ± 27.0 mm³)
groups had tumor growth suppression by 25.8% ($p < 0.15$, Welch’s $t$ test) and 60.2% ($p < 0.01$, Welch’s $t$ test), respectively. And although statistical significance was not shown, APT$_{EDB}$-DSPE-DTX group showed about a 34.4% higher tumor growth suppression than DSPE-DTX group ($p < 0.09$, Welch’s $t$ test). No significant weight change was observed in all groups during the experiment (Day 1, control = 22.7 ± 1.3 g, DSPE-DTX = 23.3 ± 2.5 g, APT$_{EDB}$-DSPE-DTX = 23.3 ± 1.6 g; Day 21, control = 24.5 ± 1.3 g, DSPE-DTX = 25.1 ± 1.7 g, APT$_{EDB}$-DSPE-DTX = 25.5 ± 1.5 g) (Figure S3C). These results suggest that our EDB-FN-targeting micellar nano-DDS has the potential to treat MG and indicate that EDB-FN is a useful target for drug therapy.

In order to confirm that implanted U87MG cells in the MG orthotopic mouse models still overexpress EDB-FN, immunohistochemistry analysis was performed using mouse brain slices containing tumor in all groups. In contrast to normal area of the mouse brain tissue, EDB-FN was highly expressed in tumoral area of all groups (Figure S4A). Interestingly, EDB-FN expression within the tumor was slightly decreased in the APT$_{EDB}$-DSPE-DTX group compared to the control and DSPE-DTX group (Figure S4B), which may suggest the possibility that APT$_{EDB}$-DSPE-DTX had an effect on tumoral EDB-FN levels.

**Discussion**

In this study, we focused on the target, EDB-FN, which is located on the surface of cancer cells and in the extracellular matrix. This is because proteins on the surface and in the extracellular matrix can provide useful targets for drug delivery systems (DDSs) as well as cancer diagnostic biomarkers [30-32]. We recently established ‘Oncopression’, a dataset that integrates separate datasets of various cancers for comprehensive analysis [19]. Among numerous specifically analyzed overexpressed markers in the dataset of patient cancer tissues, we found that EDB-FN is one of the cancer biomarkers specifically overexpressed in MG compared to other carcinomas in terms of cancer-to-normal expression levels.

Previously, we reported that EDB-FN is a useful target for multiple drug-resistant breast cancers and gliomas [33, 34]. However, most previous EDB-FN studies were based only on in vitro and in vivo results, and assessments of clinical efficacy have been limited to date. Therefore, the integration of research data and clinical databases are crucial [35]. In this study, we investigated the clinical relevance of EDB-FN by analyzing large quantitative datasets of messenger ribonucleic acid expression in patients with cancers spanning 17 different organs. Data extracted from cancers of various major organs and the corresponding normal tissue samples were integrated,
and the differences in EDB-FN expression between each cancer tissue and its corresponding normal tissue were evaluated. For brain tumors, data for samples with various pathological statuses, such as astrocytoma, GBM, oligodendroglioma, oligoastrocytoma, ependymoma, and medulloblastoma, were included. Oligoastrocytoma has been discouraged as a diagnosis since the 2016 WHO classification was published but was included in this analysis, as we collected and analyzed samples of all brain tumors accessible through open public data. To verify the usefulness of EDB-FN in MG, the scope of the analysis was readjusted to 3,687 samples from normal brains, brains harboring nontumor diseases, and tissues from patients with diagnosed astrocytoma of any grade, including GBM, with representative molecular information, and EDB-FN was found to have significantly higher expression in all grades of brain tumors than in a normal brain. Interestingly, the results of in silico analysis showed that EDB-FN has higher expression than in a normal brain in other pathological conditions such as major depressive disorder and epilepsy. This result may suggest a different meaning of EDB-FN, which has been known as an oncofetal antigen to date [30], but it is considered a matter to be confirmed through additional experimental verification in order to trust this result. In addition to quantitative comparisons of EDB-FN expression, prognostic prediction was performed in GBM, a representative MG, but there was no statistically significant difference in the overall survival according to the EDB-FN expression level.

Although big data analysis using Oncopression is information extracted from a large number of patient samples, it was necessary to reinforce the evidence through more direct experimental validation of the data. In addition, there was a need to evaluate whether the expression level of EDB-FN is correlated with progression free survival, another especially important patient prognostic endpoint for GBM patients. Therefore, we newly produced TMA slides using preserved GBM patient specimens under IRB approval. The results obtained through the TMA analysis can be summarized into the following three points; 1) EDB-FN expression could be confirmed in most tissue samples of GBM patients, suggesting that EDB-FN can be considered a diagnostic biomarker for GBM; 2) There was no significant difference in overall survival between the EDB-FN low-expression group and high-expression group, which is a result of enhancing the reliability of the Oncopression analysis data; 3) There is a significant difference in progression free survival according to the EDB-FN expression level; the EDB-FN high-expression group may have a progression risk 5.5 times higher than that of the low-expression group, which suggests that EDB-FN may serve as a prognostic biomarker for GBM patients.

Taking these results into account, we speculated that EDB-FN could be used as a diagnostic and noninvasive therapeutic drug delivery target candidate in MG, and we performed conventional in vitro and in vivo experiments for validation, including orthotopic xenograft animal model experiments. Since the BBTB often exhibits minute physiologic pore sizes of less than 20 nm, which would impede the penetration of larger DDSs, using much smaller sized nano-DDSs would ensure easy penetration through the BBTB [36, 37]. Therefore, we worked to improve our drug delivery strategy and developed an ultrasmall micelle (~12 nm) using a DSPE polymer and attached an APTed to the surface of the micelle, constructing a system that could be used for the diagnosis and treatment of MG. The size of the drug delivery system was greatly reduced from the previously used approximately 115-118 nm sized liposomes or 34 nm sized superparamagnetic iron oxide nanoparticles [33, 34, 38] to the current sub-12 nm sized micelles (Figure 3).

We quantitatively compared the expression level of EDB-FN and the patient prognostic relationship (Figure 1 and 2) and examined the usefulness of EDB-FN-targeting in MG (Figure 4 and 5). The overexpression of EDB-FN and the enhanced drug delivery by EDB-FN-targeting DDGs were shown not only in monolayer cell cultures but also in orthotopic xenograft models, which may confirm that EDB-FN is expressed in MG cells and tissues and that a nano-DDS can be linked or anchored to MG via EDB-FN-targeting (Figure 6). Although the dose of DTX for orthotopic xenograft animal models was determined as 10 mg/kg in total, which is about 33% less than 15 mg/kg in total for flank xenograft animal models, with consideration of neuronal toxicity of the DTX [39], significant antitumoral efficacy was also presented in the orthotopic models, which was shown in the flank models. Despite the limitations of BBTB, the engineered EDB-FN–targeting micelle nano-DDSs showed significant therapeutic effects compared to the non-targeting micellar nano-DDS, which had no statistically significant antitumoral efficacy. Specific binding of APTed to MG cells may have efficiently increased tumor retention time of the APTed-DSPE micellar nano-DDS, resulting in superior antitumor efficacy. EDB-FN is specifically and highly expressed in MG tissues but is minimally expressed in adjacent normal tissues and normal brain tissues. This characteristic may further contribute to the feasibility of using EDB-FN as a targeting ligand for MG treatment.
Conclusion

We elucidated the significance of EDB-FN as a potential diagnostic and prognostic biomarker for MG. To the best of our knowledge, no studies comparing EDB-FN expression levels in cancers of all major organs have been conducted, and studies involving prognostic prediction by EDB-FN expression have not been conducted using large bioinformatic datasets. As the results indicate, investigating the EDB-FN expression level in MG patients may afford useful prognostic predictions, and specific targeting of EDB-FN may provide novel therapeutic modalities for the treatment of MG.

Abbreviations

AD: Alzheimer’s disease; APTED-B: EDB-FN-specific aptamer-like peptide (aptide); APTED-B-DSPE: APTED-B-Conjugated PEG2000-DSPE; APTED-B-DSPE-DTX: DTX-loaded APTED-B-DSPE micellar nano-DDS; BBTB: blood-brain tumor barrier; DAPI: 4’,6-diamidino-2-phenylindole; DDS: drug delivery system; DLS: dynamic light scattering; DSPE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; DSPE-DTX: DTX-loaded PEG2000-DSPE micellar nano-DDS; DTX: docetaxel; EDB-FN: fibronectin with extra-domain A; EDB-FN: extra-domain B of fibronectin; GBM: glioblastoma multiforme; IDH-1: isocitrate dehydrogenase-1; IICIS-FN: type III connecting segment; Mal-PEG2000-DSPE: N-maleimide-PEG2000-DSPE (ammonium salt); MDD: major depressive disorder; MG: malignant glioma; MGMT: O6-methylguanine-DNA methyltransferase; PD: Parkinson’s disease; PEG2000: polyethylene glycol (2000); PEG2000-DSPE: polyethylene glycol (2000)-DSPE (ammonium salt); Rh-DSPE: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt); UPC: universal phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt); UPy: universal phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt); UPS: universal phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt); APTEB-DB: EDB-FN–specific aptamer-like peptide/peptide; APTED-B-DSPE: EDB-FN–specific aptamer-like peptide/peptide conjugated PEG2000-DSPE.

Acknowledgements

We would like to thank Seo Yun Hwang, Ms. So Young Lee, Dr. So Young Lee, and Soo Jin Kim for their sincere support and assistance. This work was supported by funding from the National Research Foundation of the Republic of Korea (NRF-2017R1D1A1B03028979, NRF-2019M3A9E2061791, and NRF-2019M3E5D1A01068993), the Korea University Guro Hospital Grant (O1801421), the National Natural Science Foundation of China (81874226 and 81803020), the Thousand Talents Program for Distinguished Young Scholars, the International Scientific and Technological Cooperation Program of the Guangdong Science and Technology Department (2018A050506033), and a grant from the Guangzhou Science and Technology Bureau (201704020131).

Author Contributions

PES, XX, and KC primarily conceived the project and designed the experiments, and all authors contributed to the study conception and design. PES, XX, JL, CK, JHK, THK, CC, SJ, and KC provided critical materials. PES, BRK, JL, YSL, and KC performed most of the experiments and analyzed data, and all authors supervised the experiments and analysis. PES, XX, BRK, YSL, YJN, and KC wrote the draft of the manuscript. All authors discussed the results and contributed to critical discussion and editing of the manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattos AK, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009; 18: 1061-83.
2. Huang R, Harmesen S, Samii J, Karabeber H, Pitter KL, Holland EC, et al. High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe. Theranostics. 2016; 6: 1075-84.
3. Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol. 2014; 16: 1575-84.
4. Dong X. Current Strategies for Brain Drug Delivery. Theranostics. 2018; 8: 1481-93.
5. Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, et al. Assessing CpG island methylator phenotype. 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro Oncol. 2014; 16: 1630-8.
6. Barthel FP, Wesseling P, Verhaak RGW. Reconstructing the molecular life history of gliomas. Acta Neuropathol. 2018; 135: 649-70.
7. Pekmezci M, Rice T, Molinano AM, Walsh KM, Decker PA, Hansen H, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnostic: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017; 133: 1001-16.
8. Ronca R, Sozzani S, Prema M, Alessi P. Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EBD-fibronectin antibody case. Immunobiology. 2009; 214: 800-10.
9. Ventura E, Sassi F, Parodi A, Balza E, Borsl I, Castellani P, et al. Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8. PLoS One. 2010; 5: e9145.
10. Khan ZA, Carutero J, Barbín VP, Chan BM, Uniyal S, Chakrabarti S. ED-B fibronectin in non-small cell lung carcinoma. Exp Lung Res. 2005; 31: 701-11.
11. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009; 113: 2265-74.
12. Locher R, Erba PA, Hirsch B, Bombardieri E, Giovannoni L, Neri D, et al. Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of [131I]-L19SIP in a prostate cancer patient. J Cancer Res Clin Oncol. 2014; 140: 35-43.
13. Birchler MT, Milisavljevic D, Pfaltz M, Neri D, Odermatt B, Schmid S, et al. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope. 2003; 113: 1231-7.
14. Abrecht V, Richter A, Pfeiffer S, Gebauer M, Lindner S, Gieser E, et al. Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas. Int J Cancer. 2016; 138: 1269-80.
15. Spaeth N, Wyss MT, Pahnke J, Biesel G, Trachsel E, Drandarov K, et al. Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat glioma: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19). Nucl Med Biol. 2006; 33: 661-6.
16. Saw PE, Zhang A, Nie Y, Zhang L, Xu Y, Xu X. Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy. Front Pharmacol. 2018; 9: 1194.
17. Vaidya A, Wang H, Qian Y, Gilmore H, Lu ZR. Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer Cells. Cells. 2020; 9: 1826.
18. Vaidya A, Ayat N, Buford M, Wang H, Shankardass A, Zhao Y, et al. Nominative assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin. Theranostics. 2020; 10: 11127-43.
19. Lee J, Choi C. Oncopression: gene expression compendium for cancer with matched normal tissues. Bioinformatics. 2017; 33: 2068-70.
20. Team RC. R: A language and environment for statistical computing. Vienna, Austria; 2013.
21. Piccolo SR, Withers MR, Francis OE, Bild AH, Johnson WE. Multiplatform single-sample estimates of transcriptional activation. Proc Natl Acad Sci U S A. 2015; 110: 17778-83.
22. Lipták T. On the combination of independent tests. Magyar Tud Akad Mat Kutato Int Kozl. 1958; 3: 171-97.
23. Zaykin DV. Optimally weighted Z-test is a powerful method for combining probabilities in meta-analysis. J Evol Biol. 2011; 24: 1836-41.
24. Matsui S, Takahashi T, Oyanagi Y, Takahashi S, Boku S, Takahashi K, et al. Expression, localization and alternative splicing pattern of fibronectin messenger RNA in fibrotic human liver and hepatocellular carcinoma. J Hepatol. 1997; 27: 843-53.
25. Chong K, Ku T, Saw PE, Jon S, Park BH, Choi C. Enhancement of the photocytotoxic efficiency of sub-12 nm therapeutic polymeric micelles with increased co-localisation in mitochondria. Chem Commun (Camb). 2013; 49: 11476-8.
26. Saw PE, Yu M, Choi M, Lee E, Jon S, Farokhzad OC. Hyper-cell-permeable micelles as a drug delivery carrier for effective cancer therapy. Biomaterials. 2017; 123: 118-26.
27. Ozawa T, James CD. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp. 2010; 41: e1896.
28. Motahin H, Koren A, Gruden K, Ramssak Z, Schichor C, Lah TT. Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance. Oncotarget. 2015; 6: 40998-1017.
29. Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W, et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett. 2009; 279: 13-21.
30. Kumra H, Reinhardt DP. Fibronectin-targeted drug delivery in cancer. Adv Drug Deliv Rev. 2016; 97: 101-10.
31. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2: 751-60.
32. Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C Mater Biol Appl. 2016; 60: 569-78.
33. Saw PE, Kim S, Lee IH, Park J, Yu MK, Kim M, et al. Aptide-conjugated liposome targeting tumor-associated fibronectin for glioma therapy. J Mater Chem B. 2013; 1: 4723-6.
34. Saw PE, Ji X. The Significance of Interdisciplinary Integration in Academic Research and Application. BIO Integr. 2020; 1: 2-5.
35. Sarin H, Kanevsky AS, Wu H, Brimacombe KR, Fung SH, Sousa AA, et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med. 2008; 6: 80.
36. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011; 6: 815-23.
37. Park J, Kim S, Saw PE, Lee IH, Yu MK, Kim M, et al. Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging. J Control Release. 2012; 163: 111-8.
38. Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A, et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer. 2005; 41: 1460-6.